Ophthotech Corp (OPHT) Reports Large Q1 Profit, Versus Expected Loss

Ophthotech Corp (NASDAQ: OPHT) reported Q1 EPS of $0.22, $0.97 better than the analyst estimate of ($0.75). Revenue for the quarter came in at $41.7 million versus the consensus estimate of $3.68 million.

“We remain focused on the execution of our ongoing Fovista® Phase 3 program, which is highlighted by our successful completion of patient recruitment of the first Phase 3 trial of Fovista® in combination with Lucentis®,” said David Guyer, M.D., Chief Executive Officer and Chairman of the Board of Ophthotech. “The first quarter of this year has resulted in solid progress for Ophthotech as we continue to expand and focus on the progress of our Fovista® and Zimura® AMD programs.”

For earnings history and earnings-related data on Ophthotech Corp (OPHT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c